Key facts
- Fineheart’s last known valuation is $48.8M (Dec 2021).
- It has raised $75.6M; the latest was Grant ($56.3M) in Jan 2026.
- Notable investors include European Innovation Council, MedTech Innovator, UI Investissement, Verve Ventures, European Regional Development Fund (Brandenburg) — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Fineheart
- ·The full record, as it builds
Funding rounds
No funding rounds for Fineheart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fineheart
Developer of implantable cardiac devices designed to treat cardiovascular diseases. The company's device is a novel, wirelessly powered, fully implantable mechanical circulatory support device that can optimize cardiac output while preserving the heart's innate contractility, enabling patients to restore normal cardiac output and allow heart failure patients to return to a normal quality of life.
- Sector
- Healthcare
- HQ
- Pessac, France
- Founded
- 2010
- Employees
- 88
- Website
- fineheart.fr/
- Ownership
- Privately Held (backing)
Fineheart doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fineheart shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fineheart in its N-PORT filings yet. We sweep new filings monthly.